606 related articles for article (PubMed ID: 26175217)
1. Role of RAGE in Alzheimer's Disease.
Cai Z; Liu N; Wang C; Qin B; Zhou Y; Xiao M; Chang L; Yan LJ; Zhao B
Cell Mol Neurobiol; 2016 May; 36(4):483-95. PubMed ID: 26175217
[TBL] [Abstract][Full Text] [Related]
2. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.
Prasad K
Mol Cell Biochem; 2019 Sep; 459(1-2):95-112. PubMed ID: 31079281
[TBL] [Abstract][Full Text] [Related]
3. 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1-40 brain-to-blood efflux and peripheral uptake transport.
Guo YX; He LY; Zhang M; Wang F; Liu F; Peng WX
Neuroscience; 2016 May; 322():28-38. PubMed ID: 26820600
[TBL] [Abstract][Full Text] [Related]
4. Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus.
Hong Y; Shen C; Yin Q; Sun M; Ma Y; Liu X
Neurochem Res; 2016 May; 41(5):1192-9. PubMed ID: 26738988
[TBL] [Abstract][Full Text] [Related]
5. Role of insulin resistance in Alzheimer's disease.
Cai Z; Xiao M; Chang L; Yan LJ
Metab Brain Dis; 2015 Aug; 30(4):839-51. PubMed ID: 25399337
[TBL] [Abstract][Full Text] [Related]
6. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
[TBL] [Abstract][Full Text] [Related]
8. A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid β peptide-mediated neuronal disorder.
Cai C; Dai X; Zhu Y; Lian M; Xiao F; Dong F; Zhang Q; Huang Y; Zheng Q
Appl Microbiol Biotechnol; 2016 Jan; 100(2):825-35. PubMed ID: 26496918
[TBL] [Abstract][Full Text] [Related]
9. Receptor for Advanced Glycation End Products: Dementia and Cognitive Impairment.
Singh A; Ansari VA; Mahmood T; Ahsan F; Wasim R; Shariq M; Parveen S; Maheshwari S
Drug Res (Stuttg); 2023 Jun; 73(5):247-250. PubMed ID: 36889338
[TBL] [Abstract][Full Text] [Related]
10. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.
Cho HJ; Son SM; Jin SM; Hong HS; Shin DH; Kim SJ; Huh K; Mook-Jung I
FASEB J; 2009 Aug; 23(8):2639-49. PubMed ID: 19332646
[TBL] [Abstract][Full Text] [Related]
11. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.
Deane R; Zlokovic BV
Curr Alzheimer Res; 2007 Apr; 4(2):191-7. PubMed ID: 17430246
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
13. β-Asarone Mitigates Amyloidosis and Downregulates RAGE in a Transgenic Mouse Model of Alzheimer's Disease.
Yang C; Li X; Mo Y; Liu S; Zhao L; Ma X; Fang Z; Chen J; Chen Y; Yu X; Fang S; Zhang Y; Xian S; Wang Q
Cell Mol Neurobiol; 2016 Jan; 36(1):121-30. PubMed ID: 26271288
[TBL] [Abstract][Full Text] [Related]
14. RAGE Isoforms, its Ligands and their Role in Pathophysiology of Alzheimer's Disease.
Chellappa RC; Palanisamy R; Swaminathan K
Curr Alzheimer Res; 2020; 17(14):1262-1279. PubMed ID: 33602095
[TBL] [Abstract][Full Text] [Related]
15. Schisandrin B Ameliorates ICV-Infused Amyloid β Induced Oxidative Stress and Neuronal Dysfunction through Inhibiting RAGE/NF-κB/MAPK and Up-Regulating HSP/Beclin Expression.
Giridharan VV; Thandavarayan RA; Arumugam S; Mizuno M; Nawa H; Suzuki K; Ko KM; Krishnamurthy P; Watanabe K; Konishi T
PLoS One; 2015; 10(11):e0142483. PubMed ID: 26556721
[TBL] [Abstract][Full Text] [Related]
16. Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease.
Zhang L; Postina R; Wang Y
Cell Mol Life Sci; 2009 Dec; 66(24):3923-35. PubMed ID: 19672558
[TBL] [Abstract][Full Text] [Related]
17. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
18. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
Lue LF; Yan SD; Stern DM; Walker DG
Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
[TBL] [Abstract][Full Text] [Related]
19. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
[TBL] [Abstract][Full Text] [Related]
20. Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease.
Jaya Prasanthi RP; Schommer E; Thomasson S; Thompson A; Feist G; Ghribi O
Mech Ageing Dev; 2008 Nov; 129(11):649-55. PubMed ID: 18845178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
